ROSE CLIFFORD: Open Payments
NPI 1730285602 · GAUTIER, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,031 in 45 payments from 10 companies in 2025. Trend: 2023 $6,707 · 2024 $1,280 · 2025 $1,031
Food & beverage: $1,031
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $288 |
| Axsome Therapeutics, Inc. | 8 | $210 |
| ABBVIE INC. | 10 | $172 |
| Lundbeck LLC | 4 | $93 |
| Janssen Pharmaceuticals, Inc | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| Alkermes, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: CAPLYTA, Auvelity, VRAYLAR, REXULTI, SPRAVATO, FANAPT, COBENFY, ARISTADA.
Industry payments across MS — which companies pay providers there.
